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Abstract 
Background: The expanded disability status scale (EDSS) is a validated and reliable tool to assess the extent of dis‑
abilities in patients with multiple sclerosis (MS). However, the use of this tool has been found to be limited in assess‑
ing various symptoms of MS that are important. Our study aimed at evaluating the efficacy of a new scoring system, 
reverse nutech functional score (RNFS) as compared to EDSS in assessing patients with MS treated with human 
embryonic stem cell (hESC) therapy.
Methods: The MS patients were treated with hESC therapy for one treatment period. All the patients were evaluated 
with EDSS and RNFS at baseline and after the hESC therapy.
Results: The study included a total of 24 MS patients with mean age of 45 year. The patients showed an improve‑
ment in parameters (sleeping disorders, paralysis, paraesthesia, myalgia, muscle weakness, memory, language, irritabil‑
ity, eye pain, depression and coordination, communication, breathing pattern, attention and appetite) associated with 
MS when evaluated with RNFS. This improvement went unnoticed when the patients were assessed with EDSS.
Conclusion: RNFS can efficiently assess the effectiveness of hESC therapy in treating patients with MS. It could be a 
suitable scoring system for patients with MS as it can assess the slightest improvements in the patients. Use in other 
settings would be helpful in assessing its utility.
Keywords: Multiple sclerosis, Reverse nutech functional score (RNFS), Human embryonic stem cell (hESC),  
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Background
Multiple sclerosis (MS) is an autoimmune, chronic 
inflammatory demyelinating disease of the central 
nervous system (CNS) with genetic and environmen-
tal effects, among young and middle-aged adults [1, 2]. 
It affects around 2.5 million people worldwide and is 
the third most common neurologic disorder cited as 
the cause of disability [3]. According to the Centers for 
Disease Control and Prevention (CDC), approximately 
85  % of the affected people have a relapsing-remitting 
course, characterized by an unpredictable course of 
exacerbations and remissions [4]. The diagnosis of MS is 
based on the lesions present in the CNS which appears in 
the different areas of brain [5].
The rate of growth of the disease is extremely mutable 
and uncertain, with an unclear etiology. Presently there is 
no cure, and only symptomatic therapy is available. Gen-
erally, oral or intravenous corticosteroids like methyl-
prednisolone is used at a high dose in the routine therapy 
for acute attacks which results in a faster recovery from 
the disability within a duration of three to five  days of 
course [6]. However, the corticosteroid therapy does not 
have a significant impact on the long term disability [7]. 
The improvement in therapy is measured by means of 
expanded disability status scale (EDSS) [8].
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Basically, EDSS quantifies disability in eight functional 
systems (FS) and allows neurologists to assign a func-
tional systems scores (FSS) in each of these systems. It 
consists of ordinal rating system ranging from 0 (normal 
neurological status) to 10 (death due to MS) in 0.5 incre-
ments interval (when reaching EDSS 1) [8]. EDSS also 
has a number of limitations. It is dependent on mobility 
of patient. It is subjective in certain areas (e.g., bowel and 
bladder function). It is also insensitive to small changes. 
Further, it does not present an accurate picture of the 
patient’s cognitive and functional abilities in performing 
activities of daily living (ADLs). It is nonlinear in terms of 
the time spent at various ranges of the scale [9].
We have previously published a case study of a patient 
with MS, who was treated with human embryonic stem 
cell therapy (hESC) and was assessed with EDSS before 
and after the therapy [10]. We have also developed a 
new functional, directional and positional scoring sys-
tem, reverse nutech functional score (RNFS) to assess the 
patients with MS [11]. In the current study, we compared 
the two scoring systems, viz., RNFS and EDSS in patients 
with MS who underwent a single session of hESC therapy.
Methods
The RNFS scoring system assesses a symptom based 
on five ordinal grades that runs in a direction of 
GOOD → BAD. The RNFS system is also useful in con-
ducting probability based studies as these scores have 
been converted into numeric values. It is a numeric scale 
that scores all the known symptoms for patients with 
MS. RNFS for MS is a 36-point positional (i.e., symptoms 
were sub-graded with a specific score) and directional 
(i.e., from level 1 to 5) scoring system that can be used to 
assess or validate the diagnosis of patients with MS [11] 
whereas EDSS is a scoring system which quantifies dis-
ability in eight FS. An improvement in the symptoms was 
determined on the basis of two criteria referred as W1 
and W2, where W1 = number of cases by symptom that 
score < best possible grade (BPG) at the time of admis-
sion or at baseline (BL) and reached BPG at the end of 
therapy (ET); W2 =  number of cases by symptom that 
scored differently later by at least one grade of RNFS/
EDSS as compared to the scores at BL. W1 represented 
the positive effect of hESC therapy to cure MS whereas 
W2 exhibited the effect, whether negative, neutral or 
positive, on the condition of a MS patient.
The establishment and characterization of hESCs were 
explained in our previous paper [12]. All the patients 
were assessed for hypersensitivity reactions to hESC by 
subcutaneous (s.c.) injection of 0.25  mL hESCs. Subse-
quent to safety evaluation, hESCs were administered via 
intramuscular (i.m.) route (twice daily) to “prime” the 
body, 1 mL hESCs (<16 million cells) were administered 
via intravenous (i.v.) route (twice every 7 days) to “home 
in” to the required area and 1–5 mL hESCs were admin-
istered via any of the supplemental routes including bra-
chial plexus block, intrathecal, epidural catheter caudal, 
epidural and popliteal block and/or deep spinal muscle 
(every 7  days). All the patients received nasal sprays of 
1 mL hESCs (3.5 million cells) twice a week to enhance 
the absorption of hESCs to the brain. The detailed meth-
odology has been presented in Fig. 1. The safety studies 
of hESCs were explained in our previous paper [13].
In this study, the patients with MS were assessed with 
RNFS and EDSS. The RNFS/EDSS scores before and 
after the therapy were compared to assess which scor-
ing system is better in evaluating the patients treated 
with hESC therapy. All the patients provided written 
informed consent prior to start of the study. The study 
was conducted in accordance with Declaration of Hel-




A total of 24 patients with a mean age of 45  year were 
enrolled in the current study. The days of treatment 
in T1 varied from 42 to 84  days with a gap phase of 
120–240 days.
Patient wise status of EDSS grade at the ET
Out of 24 patients, only one patient reached the BPG 
at ET and 21 patients showed change in grade after the 
treatment (Table 1).
Fig. 1 Schematic diagram for methodology. RNFS reverse nutech functional score; EDSS expanded disability status scale; hESC human embryonic 
stem cell; sc subcutaneous; iv intravenous
Page 3 of 6Shroff  Clin Trans Med  (2016) 5:43 
Cases that scored less than BPG at BL and reached BPG 
afterwards
Number of affected parameters varied among the 
patients. Except five patients, all other patients showed 
an improvement (Table 2).
Cases that scored differently later by at least one grade 
of RNFS
All the patients scored differently by at least one grade. 
One of the patient had 22 parameters that scored <BPG 
at BL and after the therapy, 20 (90.9  %) parameters 
improved by at least one grade Table 3.
Parameters that scored less than BPG at BL and reached 
BPG afterwards
The scores for cases have also been categorized based on 
the affected parameters. Muscle weakness, an important 
symptom of MS, was scored to be as <BPG in all the cases 
at BL. At ET, 3 (12.5  %) patients reached BPG. Fatigue 
was scored as <BPG in 22 cases at BL, 8 (36.4 %) of them 
reached BPG at ET. The scores of all other parameters are 
presented in Table 4.
Discussion
In this study, an improvement in condition of the patients 
was evaluated more efficiently with RNFS system by 
highlighting even the slightest improvement. The lev-
els in RNFS run in direction 1 (Good)  →  5 (Bad) and 
patients could be placed in these levels on the basis of 
their symptoms and functional limitations.
Gray and Butzkueven stated that EDSS is subjective in 
certain areas (e.g., bowel and bladder function). It is also 
insensitive to small changes. Further, it does not present 
an accurate picture of the patient’s cognitive abilities and 
functional abilities in performing ADLs. It is nonlinear 
in terms of the time spent at various ranges of the scale 
[14]. Moreover, the practitioners and staff of our institute 
observed that EDSS emphasize mainly on the mobility of 
MS patients. The system is unable to assess other impor-
tant parameters such as; sleeping disorders, paralysis, 
Table 1 Patient wise status of  EDSS grade at  the end 
of therapy
EDSS expanded disability status scale; BPG best possible grade
Patient code Age (years) Gender Reached BPG Change 
in grade
80806 29 M No Yes
80926 35 M No Yes
81128 64 M No No
80680 61 M No Yes
80710 43 M No Yes
80488 32 M No Yes
80499 61 M No Yes
80723 25 M No Yes
80981 56 F Yes Yes
80889 33 F No Yes
81238 30 F No Yes
81275 34 F No Yes
81114 54 F No Yes
81249 45 F No Yes
81296 30 F No Yes
80568 53 F No Yes
80626 54 F No Yes
80562 47 F No Yes
80768 57 F No Yes
81105 57 F No Yes
80673 32 F No Yes
80637 41 F No Yes
81187 53 F No No
81180 41 F No No
Table 2 Patient wise number of  parameters that  scored 
less than  the best possible grade (<BPG) at  baseline 
and reached BPG afterwards
BPG best possible grade
Patient code Number of affected 
parameters (<BPG)
Parameters improved 
at end of therapy; n (%)
80488 22 6 (27.3)
80499 12 6 (50.0)
80680 11 0
80710 15 9 (60.0)
80723 12 6 (50.0)
80806 2 1 (50.0)
80926 4 0
81128 10 3 (30.0)
80562 17 2 (11.8)
80568 17 1 (5.9)
80626 14 5 (35.7)
80637 15 2 (13.3)
80673 10 1 (10.0)
80768 13 1 (7.7)
80889 8 3 (37.5)
80981 5 3 (60.0)
81105 12 1 (8.3)
81114 6 0
81180 17 2 (11.8)
81187 7 0
81238 4 3 (75.0)
81249 9 1 (11.1)
81275 9 1 (11.1)
81296 8 0
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paraesthesia, myalgia, muscle weakness, memory, lan-
guage, irritability, eye pain, depression, coordination, 
communication, breathing pattern, attention and appe-
tite that were important to gauge in a patient with MS.
Schwid et al. reported in the study for comparing limi-
tations of walking ability in MS patients, the EDSS and 
ambulation index (AI) were less sensitive to change than 
the D max (the maximum distance that a person can go) 
and T8 (time to walk 8  m) [15]. Similarly, Vaney et  al. 
reported lesser changes in EDSS than in the Rivermead 
mobility index (RMI), the AI and the 10 m walking time 
test [16]. Hohol et  al. reported a lower sensitivity to 
change in EDSS compared with disease steps [17]. Healy 
et  al. conducted a study to assess the sustained disease 
progression in relapsing-remitting multiple sclerosis 
Table 3 Patient wise number of  cases who scored differ-
ently later by at least one grade of RNFS score at baseline
RNFS reverse nutech functional score; BL baseline; BPG best possible grade
patient code Number of affected 
parameters at BL 
(<BPG)






80488 22 2 (9.1) 20 (90.9)
80499 12 3 (25.0) 9 (75.0)
80680 11 0 11 (100.0)
80710 15 3 (20.0) 12(80.0)
80723 12 3 (25.0) 9 (75.0)
80806 2 1 (50.0) 1 (50.0)
80926 4 2 (50.0) 2 (50.0)
81128 10 4 (40.0) 6 (60.0)
80562 17 0 17 (100.0)
80568 17 4 (23.5) 13 (76.5)
80626 14 4 (28.6) 10 (71.4)
80637 15 9 (60.0) 6 (40.0)
80673 10 5 (50.0) 5 (50.0)
80768 13 7 (53.8) 6 (46.2)
80889 8 3 (37.5) 5 (62.5)
80981 5 0 5 (100.0)
81105 12 6 (50.0) 6 (50.0)
81114 6 5 (83.3) 1 (16.7)
81180 17 10 (58.8) 7 (41.2)
81187 7 4 (57.1) 3 (42.9)
81238 4 0 4 (100.0)
81249 9 6 (66.7) 3 (33.3)
81275 9 8 (88.9) 1 (11.1)
81296 8 6 (75.0) 2 (25.0)
Table 4 Parameter wise number of  patients who scored 
less than  the best possible grade (<BPG) at  baseline 
and reached BPG afterwards
BPG best possible grade





Appetite 7 7 (100.0)




Balance—eyes open in 
straight line
24 3 (12.5)
Bladder—control 12 2 (16.7)
Bladder—sensation 8 2 (25.0)
Bowel—control 6 1 (16.7)








Deformity 8 1 (12.5)
Depression 6 4 (66.7)
Double‑vision + color 
blindness
5 1 (20.0)
Ears—hearing 3 3 (100.0)
Eye pain 2 2 (100.0)
Fatigue 22 8 (36.4)
Floaters 2 1 (50.0)
Irritability 7 4 (57.1)
Language 3 1 (33.3)
Limb tremors 15 6 (40.0)
Memory 7 5 (71.4)
Muscle weakness 27 3 (11.1)
Myalgia 11 5 (45.5)
Orientation—yes or no 1 1 (100.0)
Pain 18 7 (38.9)
Paralysis 5 0
Paraesthesia 11 5 (45.5)
Physical—drooling 1 1 (100.0)







Stiffness 19 10 (52.6)
Tingling 7 3 (42.9)
Tinnitus 3 3 (100.0)
Vision—blurring 11 3 (27.3)
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(RRMS) with EDSS. The author found, between 15.8 and 
42.2  % of patients experienced sustained progression 
based on the definitions using EDSS as the outcome, but 
nearly 50 % of these patients failed to maintain sustained 
progression for the duration of follow-up. The author 
concluded that short-term changes in the EDSS scores 
may not be an accurate marker of irreversible change in 
RRMS [18]. It has been difficult for clinicians to make 
normative evaluations of patient’s motor potency with 
EDSS. However, RNFS system is a functional and para-
metric system that assesses a patient with MS on the 
basis of all the parameters that were associated with MS. 
In our study, RNFS identified even the smallest change in 
the parameters of MS. Figure  2 show the list of disease 
related parameters that are assessed by RNFS but not by 
EDSS.
Use of hESC therapy has generally led to a concern 
because of clinical non-viability in culturing of cells in 
a xeno-free environment. However, our institution uses 
a patented methodology [19] for the extraction, isola-
tion and maintenance of hESCs [12, 13]. The ability of 
stem cells to proliferate and to reconstruct the damaged 
parts offers excellent possibilities [20]. Previous studies 
have shown the potential of stem cells to migrate at 
the injury site and commence host repair and healing 
via the direct or indirect cell-signalling. In the course 
of brain injury, stem cells initiate neuroprotection and 
neural repair by inflammatory suppression, causing tis-
sue reconstruction and avert cell damage. We have also 
reported the efficacy of hESCs in patients with MS [10]. 
The current study highlights the effectiveness of hESC 
therapy (as per the findings of RNFS and EDSS assess-
ment) in the treatment of patients with MS. However, 
the assessment of MS lesions using gadolinium dye is 
warranted. Advances in this field are required to sub-
stantiate the efficacy results.
Conclusion
The RNFS is a solitary classification system for the 
patients of all ages with diminished complexity of the 
assessment system for the practitioners. So, we conclude 
that the newly developed RNFS is a unique tool can be 
used to gauge the betterment of patients receiving hESC 
therapy. Thus, this newly developed classification, func-
tional and evaluation system can be used globally to help 
the patients with MS.
Fig. 2 Parameters covered by reverse nutech functional score but not by expanded disability status scale. RNFS reverse nutech functional score; 
EDSS expanded disability status scale
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remitting multiple sclerosis.
Acknowledgements
The author acknowledges all the doctors, staff and patients of the Nutech 
Mediworld. The author also acknowledges Knowledge Isotopes Pvt. Ltd. 
(http://www.knowledgeisotopes.com) for the medical writing assistance.
Competing interests
The author declares that she has no competing interests.
Ethics approval and consent to participate
The study was conducted in accordance with Declaration of Helsinki and 
approved by an independent Institutional Ethics Committee (IEC). All the 
patients provided written informed consent prior to start of the study.
Received: 5 September 2016   Accepted: 5 October 2016
References
 1. Wingerchuk DM, Carter JL (2014) Multiple sclerosis: current and emerging 
disease‑modifying therapies and treatment strategies. Mayo Clin Proc 
89(2):225–240
 2. International Multiple Sclerosis Genetics Consortium, Wellcome Trust 
Case Control Consortium, Sawcer S, Hellenthal G, Pirinen M, Spencer CC 
et al (2011) Genetic risk and a primary role for cell‑mediated immune 
mechanisms in multiple sclerosis. Nature 476(7359):214–219
 3. Bethoux F, Bennett S (2011) Evaluating walking in patients with multiple 
sclerosis: which assessment tools are useful in clinical practice? Int J MS 
Care 13(1):4–14
 4. Noonan CW, Williamson DM, Henry JP, Indian R, Lynch SG, Neuberger JS 
et al (2010) The prevalence of multiple sclerosis in 3 US communities. 
Prev Chronic Dis 7(1):A12
 5. Calabresi PA (2004) Diagnosis and management of multiple sclerosis. Am 
Fam Physician 70(10):1935–1944
 6. Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P 
et al (2005) EFNS guideline on treatment of multiple sclerosis relapses: 
report of an EFNS task force on treatment of multiple sclerosis relapses. 
Eur J Neurol 12(12):939–946
 7. Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C (2008) Cor‑
ticosteroids for the long‑term treatment in multiple sclerosis. Cochrane 
Database Syst Rev 1:CD006264
 8. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an 
expanded disability status scale (EDSS). Neurology 33(11):1444–1452
 9. Sharrack B, Hughes RA, Soudain S, Dunn G (1999) The psychometric 
properties of clinical rating scales used in multiple sclerosis. Brain 122(Pt 
1):141–159
 10. Shroff G (2015) Human embryonic stem cell for the treatment of multiple 
sclerosis: a case report. Case Rep Int 4:38–42
 11. Shroff G (2015) Scoring system approach of reverse Nutech functional 
score to assess patients with multiple sclerosis. J Neurol Transl Neurosci 
4(2):1066
 12. Shroff G (2015) Establishment and characterization of a neuronal cell line 
derived from a 2‑cell stage human embryo: clinically tested cell‑based 
therapy for neurological disorders. Int J Recent Sci Res 6(4):3730–3738
 13. Shroff G, Barthakur JK (2015) Safety of human embryonic stem cells in 
patients with terminal/incurable conditions—a retrospective analysis. 
Ann Neurosci 22(3):132–138
 14. Gray O, Butzkueven H (2008) Measurement of disability in multiple sclero‑
sis. Neurol Asia 13:153–156
 15. Schwid SR, Goodman AD, Apatoff BR, Coyle PK, Jacobs LD, Krupp LB et al 
(2000) Are quantitative functional measures more sensitive to worsening 
MS than traditional measures? Neurology 55(12):1901–1903
 16. Vaney C, Blaurock H, Gattlen B, Meisels C (1996) Assessing mobility in 
multiple sclerosis using the Rivermead mobility index and gait speed. 
Clin Rehabil 10(3):216–226
 17. Hohol MJ, Orav EJ, Weiner HL (1995) Disease steps in multiple scle‑
rosis: a simple approach to evaluate disease progression. Neurology 
45(2):251–255
 18. Healy BC, Engler D, Glanz B, Musallam A, Chitnis T (2013) Assessment 
of definitions of sustained disease progression in relapsing‑remitting 
multiple sclerosis. Mult Scler Int 2013:189624
 19. World Intellectual Property Organization. 21. (WO2007141657) Composi‑
tions comprising human embryonic stem cells and their derivatives, 
methods of use, and methods of preparation. https://www.patentscope.
wipo.int/search/en/detail.jsf?docId=WO2007141657&recNum=21&max
Rec=21&office=&prevFilter=&sortOption=Pub+Date+Desc&queryStrin
g=FP%3A(geeta+shroff )&tab=PCTDescription. Accessed 20 Aug 2016
 20. Ul Hassan A, Hassan G, Rasool Z (2009) Role of stem cells in treatment of 
neurological disorder. Int J Health Sci (Qassim) 3(2):227–233
